Carlsmed closed an oversubscribed USD $2.5 million seed round.
Carlsmed leverages artificial intelligence and predictive analytics to transform surgical planning processes from 2-D methods to 3-dimensional patient-specific models. The financing will support the clinical launch of the aprevo™ system of proprietary planning tools and personalized implants based on the patient’s pathology. An aprevo anterior implant is pictured above.
Last year, Carlsmecd merged with Precisive Surgical to develop what it plans to be the industry’s first end-to-end personalized surgical workflow platform.
The round was led by Cove Fund II. Medtech fund participants include Wavemaker Three-Sixty Health and Device of Tomorrow Capital, as well as individual investors.
“We are very bullish about the prospects for Carlsmed,” said Mike Benvenuti, Co-Manager of Cove Fund II. “Carlsmed’s team has the deep industry experience and operational expertise to lead the much needed shift to personalized medicine for challenging complex spine cases and beyond.”
Carlsmed closed an oversubscribed USD $2.5 million seed round.
Carlsmed leverages artificial intelligence and predictive analytics to transform surgical planning processes from 2-D methods to 3-dimensional patient-specific models. The financing will support the clinical launch of the aprevo™ system of proprietary planning tools and...
Carlsmed closed an oversubscribed USD $2.5 million seed round.
Carlsmed leverages artificial intelligence and predictive analytics to transform surgical planning processes from 2-D methods to 3-dimensional patient-specific models. The financing will support the clinical launch of the aprevo™ system of proprietary planning tools and personalized implants based on the patient’s pathology. An aprevo anterior implant is pictured above.
Last year, Carlsmecd merged with Precisive Surgical to develop what it plans to be the industry’s first end-to-end personalized surgical workflow platform.
The round was led by Cove Fund II. Medtech fund participants include Wavemaker Three-Sixty Health and Device of Tomorrow Capital, as well as individual investors.
“We are very bullish about the prospects for Carlsmed,” said Mike Benvenuti, Co-Manager of Cove Fund II. “Carlsmed’s team has the deep industry experience and operational expertise to lead the much needed shift to personalized medicine for challenging complex spine cases and beyond.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
